Vaccine aims to outsmart drug resistance in ALK-Positive lung cancer

NCT ID NCT05950139

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This pilot study is testing a peptide vaccine designed to prevent or delay resistance in people with advanced ALK-positive lung cancer who are already on targeted therapy. The vaccine targets ALK protein mutations to boost the immune system. The study will enroll 12 participants and primarily check for safety and immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peptide vaccine
What this could lead to: If it works, this vaccine could help delay or prevent resistance to ALK-targeted therapy, potentially extending the time patients benefit from their current treatment.
What could go wrong: This is a very early, small pilot study with only 12 participants. The vaccine may not trigger a strong enough immune response or could cause side effects. Success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK FUSION PROTEIN EXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK FUSION PROTEIN EXPRESSION NSCLC STAGE IV

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.